Aztreonam
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Aztreonam: From Gram-Negative Bacterial Infections to Gonococcal Urethritis
One-Sentence Summary
Aztreonam is a monobactam (monocyclic β-lactam) antibiotic with exclusive activity against aerobic gram-negative bacteria, used to treat serious gram-negative infections. The TxGNN model predicts it may be effective for Gonococcal Urethritis — the highest-evidence candidate across all ten predictions in this analysis — with 1 clinical trial and 8 publications currently supporting this direction. While the top-ranked TxGNN prediction by score is polyclonal hyperviscosity syndrome (score 99.73%), that indication carries no supporting evidence (L5); this report therefore focuses on gonococcal urethritis (TxGNN rank 4, score 99.59%, evidence level L2), which represents the most clinically actionable finding.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Gram-negative bacterial infections (no UK marketing authorisation on record) |
| Predicted New Indication | Gonococcal Urethritis |
| TxGNN Prediction Score | 99.59% |
| Evidence Level | L2 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known information, Aztreonam is the only clinically used drug in the monobactam class — a monocyclic β-lactam that acts by binding with high affinity to penicillin-binding protein 3 (PBP3) on aerobic gram-negative bacteria, disrupting cell wall synthesis and inducing bacterial lysis. It has no clinically meaningful activity against gram-positive organisms or anaerobes, which defines it as a highly selective narrow-spectrum agent.
Neisseria gonorrhoeae is an aerobic gram-negative diplococcus — precisely the bacterial class that Aztreonam targets. In the context of a global antimicrobial resistance (AMR) crisis, where N. gonorrhoeae has developed resistance to every major first-line antibiotic class (penicillins, fluoroquinolones, and most recently cephalosporins), aztreonam’s PBP3-binding mechanism offers a biologically distinct alternative. The Public Health England (now UKHSA) and CDC have both designated drug-resistant gonorrhoea as an urgent public health threat. Aztreonam’s activity against N. gonorrhoeae — including penicillinase-producing strains (PPNG) — has been documented since the early 1980s.
The repurposing rationale is therefore mechanistically well-grounded, not speculative. The organism is gram-negative, the drug targets a conserved PBP on gram-negative bacteria, and clinical evidence spans over four decades. The most recent Phase 2/3 trial (completed 2019) specifically evaluated aztreonam as a salvage regimen for pharyngeal gonorrhoea — the hardest anatomical site to eradicate and the main driver of onward transmission and resistance selection — further strengthening the biological and epidemiological case.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT03867734 | Phase 2/3 | Completed | 32 | Single-dose intramuscular aztreonam 2 g for pharyngeal N. gonorrhoeae in men; conducted April–September 2019; evaluated as a novel regimen against AMR gonorrhoea at the CDC-identified priority anatomical site; provides initial dose and early efficacy data directly applicable to gonococcal urethritis |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33077658 | 2020 | Single-arm clinical trial | Antimicrobial Agents and Chemotherapy | Open-label trial of single-dose IM aztreonam 2 g in men; evaluated pharyngeal eradication of N. gonorrhoeae; supports repurposing as a ceftriaxone-resistant gonorrhoea alternative |
| 3157346 | 1985 | Clinical effectiveness study | Antimicrobial Agents and Chemotherapy | Aztreonam 1 g IM vs spectinomycin 2 g IM for uncomplicated gonorrhoea; no treatment failures with either drug across urethral, rectal, and endocervical sites |
| 3095216 | 1986 | Single-dose clinical trial | Genitourinary Medicine | Aztreonam 1 g IM cleared N. gonorrhoeae in 61 men and 26 women at all anatomical sites; effective against both penicillin-sensitive and penicillin-resistant strains; well tolerated with no adverse effects |
| 6225808 | 1983 | Clinical/microbiological study | Journal of Infectious Diseases | Early demonstration of aztreonam efficacy against PPNG, including strains also resistant to spectinomycin; established activity against multidrug-resistant N. gonorrhoeae |
| 6438364 | 1984 | Controlled clinical study | Japanese Journal of Antibiotics | 30 male patients with gonococcal urethritis treated with aztreonam; 61 N. gonorrhoeae strains characterised including 15% PPNG; bacteriological and clinical outcomes reported |
| 3937450 | 1985 | Epidemiological/therapeutic study | Acta Urologica Japonica | Single-shot aztreonam therapy in gonorrhoeal infections; 244 clinical strains evaluated; epidemiological profiling with therapeutic outcome data across a large patient cohort |
| 6226596 | 1983 | Early clinical study | Giornale Italiano di Dermatologia e Venereologia | Early clinical evaluation of aztreonam in acute gonococcal urethritis; one of the first reports of monobactam activity in gonorrhoea |
| 11406757 | 2001 | Resistance surveillance | Journal of Infection and Chemotherapy | Documents emergence of cephem- and aztreonam high-resistant N. gonorrhoeae without beta-lactamase production; underscores the need for ongoing susceptibility monitoring if aztreonam is adopted |
UK Market Information
Aztreonam currently holds no marketing authorisations in the United Kingdom. There are no MHRA-licensed products, no NICE technology appraisals, and no BNF-listed indications on record for this drug.
Note for prescribers: In the absence of a UK marketing authorisation, any clinical use would require a Specials Licence or named-patient basis under MHRA Regulations 167 and 168. Clinicians should also consult the current UKHSA/BASHH gonorrhoea treatment guidelines before considering any unlicensed use. The relevant international SmPCs (EMA/FDA) should be reviewed as a proxy for safety and dosing information.
Safety Considerations
Please refer to the SmPC (international) and BNF for safety information. As Aztreonam holds no UK marketing authorisation, no MHRA-approved labelling is available. Report any suspected adverse reactions via the Yellow Card Scheme (yellowcard.mhra.gov.uk).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A completed Phase 2/3 clinical trial (NCT03867734) combined with eight supporting publications spanning 1983–2020 consistently demonstrate aztreonam’s efficacy against Neisseria gonorrhoeae, including drug-resistant strains. The mechanistic link is strong (PBP3 inhibition in an aerobic gram-negative organism), the unmet clinical need is urgent (WHO/UKHSA AMR priority pathogen), and the drug class offers a distinct resistance profile from current first-line cephalosporins.
To proceed, the following is needed:
- Resistance surveillance data: The 2001 literature (PMID 11406757) documents emergence of non-beta-lactamase-mediated aztreonam resistance; current UK/European N. gonorrhoeae susceptibility data must be obtained before clinical adoption
- UK regulatory pathway: An MHRA marketing authorisation or Specials Licence application is required; engagement with MHRA and UKHSA is recommended at the earliest stage
- Larger randomised controlled trial: The sole completed trial enrolled only 32 participants; a powered RCT is needed to support regulatory submission and guideline inclusion
- Full pharmacokinetic data by anatomical site: Urethral, pharyngeal, and rectal PK/PD data are needed to confirm target attainment across all relevant sites
- Mechanism of action (MOA) dossier: Formal DrugBank/SmPC retrieval to address the identified data gap (DG002) and complete safety profiling
- Alignment with BASHH guidelines: Formal review by the British Association for Sexual Health and HIV to assess integration into national gonorrhoea treatment pathways
This report is for research purposes only and does not constitute medical advice. All repurposing candidates require clinical validation before therapeutic application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.